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This expert consensus aims to provide guidance for the manage-
ment of patients receiving one or multiple shocks from an ICD.
The document expresses the view of a multidisciplinary group of
experts in the fields of general adult cardiology, ICD treatment,
invasive electrophysiology, and psychosomatic medicine. A
variety of clinical settings, including emergency medicine, general
cardiology, and interventional electrophysiology, are addressed as
well as the different groups of clinicians involved in the care of
these patients. To cover different levels of expertise in ICD treat-
ment, it is intended to provide comprehensive information ranging
from a basic explanation of how an ICD works to specialist advice
for device programming.
Background
Almost 30 years after the first human implants, ICD therapy has
become the treatment of choice in patients at risk of developing
malignant ventricular arrhythmias.1,2 Accordingly, the number of
patients implanted with an ICD has increased substantially over
the past decade,3 mainly as a consequence of the expansion of
ICD indications into the field of primary prevention of SCD in
patients with decreased left ventricular function. In 2008,
120 000 patients received an ICD worldwide.3 As a result of
the growing number of ICD patients, ICD-related problems are
increasingly encountered and patients with one or multiple
shocks are to day frequently seen at emergency departments, hos-
pital wards, or ICD clinics. Therefore, personnel working in these
environments should have specific knowledge concerning the man-
agement of ICD-related problems.
* Corresponding author. Tel: +46 8 51771629; fax: +46 8 311044, Email: frieder.braunschweig@karolinska.se
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Table 1 summarizes the most common causes of ICD shocks.
Trials reported appropriate therapies in 17–64% of patients,
whereas inappropriate shocks, most often caused by supraventri-
cular tachycardia, occurred in 10–24%.4 Among patients enrolled
in primary prevention ICD trials, women experienced less appro-
priate ICD interventions than men.5 Modern device algorithms
facilitate effective termination of VT without shock delivery by
ATP, discrimination between supraventricular tachycardia and
VT, and prolonged detection windows. Therefore, we consider
shocks delivered to terminate non-life-threatening or non-severely
symptomatic arrhythmia as ‘unnecessary’. Although patients gener-
ally report the number of perceived shocks with reasonably accu-
racy,6 phantom shocks, a sensation of ICD therapies that cannot be
confirmed by device interrogation, may occasionally occur.
Patients who received shock therapies should be subjected to a
careful assessment of their clinical status and device function. ICD
shocks are a powerful risk marker for subsequent clinical events. In
patients with a primary preventive ICD indication, both appropri-
ate and inappropriate shocks are associated with a marked increase
in mortality, particularly due to death from progressive heart
failure.7,8 Possible explanations for this association include that
arrhythmia on the ventricular and/or supraventricular level can
be a harbinger of deteriorating heart failure, but it has also be pro-
posed that defibrillator shocks cause cellular damage and exert
negative inotropic effects, especially in patients receiving multiple
therapies.9 –11
Importantly, ICD shocks are often a very unpleasant experience
and may cause acute and chronic psychological distress, anxiety,
and decreased quality of life.12 Consequently, assessment and
therapy to relieve distress and anxiety should be an integral part
of treatment algorithms for post-shock ICD patients. In addition,
early catheter ablation has recently been shown significant
benefit in ICD recipients13,14 and should be considered in shock
patients.
The management of patients receiving ICD shocks is often
complex and involves a variety of specialties and professions.
Often, clinicians with no specialized training in the field feel
uncomfortable taking responsibility for ICD patients. However,
the increasing number of patients presenting after shock delivery
makes it compulsory to ensure that appropriate treatment is deliv-
ered throughout the chain of care, in particular during the initial
phase after shock delivery.
How the implantable cardiac
defibrillator works
An ICD system consists of a pulse generator, usually implanted
below the left or the right clavicle, and one to three thin electro-
des placed transvenously into different chambers of the heart
(Figure 1). One electrode is always inserted in the right ventricle
(in case this being the only lead, the system is called a ‘single-
chamber ICD’). In many patients, a dual-chamber ICD with a
right atrial and a right ventricular lead is implanted. Selected
patients with heart failure may receive an additional left ventricular
electrode placed through the coronary sinus in a posterolateral
epicardial vein [CRT ICD (CRT-D)].
The ICD has all sensing and pacing capabilities of a conventional
bradycardia pacemaker. In addition, it is designed to detect poten-
tially harmful ventricular arrhythmias and to terminate these by
either ATP or shock treatment. The defibrillation lead contains a
coil at the level of the right ventricle and, optionally, another
one in the superior vena cava (called the proximal coil). For
shock treatment, electrical current (energy ranging from ,1 to
42 J) is delivered between the ventricular defibrillation coil, the
device can, and the proximal defibrillation coil.
The detection windows for VT and VF as well as the sequence
of treatment (ATP, low-energy shock, high-energy shock) can be
individually programmed. Software algorithms enable the discrimi-
nation between atrial and ventricular arrhythmias. However, inap-
propriate shocks still occur (Table 1).
Current generation ICDs store information from various diag-
nostic features including intracardial ECG registrations during
arrhythmia and can transmit these data using remote monitoring
technology. Furthermore, the device can generate audible alarms
in the case of device malfunction, low battery capacity, and/or
lead failure.
Patient management in the acute
setting
Implantable cardiac defibrillator shocks may be related to a variety
of conditions (Table 1); thus, clinical presentations range from mild
discomfort to severe haemodynamic compromise. The shock
experience itself, varying considerably between individuals from
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being ‘hardly noticeable’ to being ‘hit with a bat’ or ‘stack with a
knife’, has been rated on average a ‘6’ on a 0–10 pain scale.6,15
The shock experience, the underlying cardiac conditions, or both
are often associated with significant symptoms, prompting the
patient to seek acute medical support by calling emergency ser-
vices, going to a hospital emergency department or calling the
responsible ICD centre.6 Today, device-related information can
also be checked using remote home monitoring systems.16
Owing to the possible underlying clinical instability
and the potential severity of symptoms, we recommend
that patients who experience one or more ICD shocks
are evaluated by a clinical expert in due course. This
should include a general clinical assessment of the patient and an
interrogation of the device in order to establish the cause and
appropriateness of therapy delivery. This section summarizes
current recommendations regarding acute post-shock manage-
ment of ICD patients.
(1) Out-of hospital setting
After experiencing a device shock, the patient or his kin need to
establish appropriate contact to a healthcare provider (Figure 1).
Detailed instructions should be given early after device implan-
tation, preferably prior to hospital discharge.
† Single shock or two shocks delivered within a short
sequence (seconds to minutes).
– In the absence of persisting severe symptoms (e.g. chest pain,
shortness of breath, rapid palpitations, confusion, significant
anxiety, or distress), the ICD clinic (i.e. the healthcare provi-
der responsible for device follow-up) should be contacted
within the next working day to initiate device interrogation
(in office or remote) and appropriate clinical assessment.
– In the presence of persisting severe symptoms (e.g. chest
pain, shortness of breath, rapid palpitations, confusion, signifi-
cant anxiety, or distress), there is a need for immediate
Figure 1 ICD schematic and post-shock emergency algorithm.










medical evaluation through a hospital Emergency Depart-
ment or the ICD clinic.
† Multiple shocks (within minutes or hours)
Need for immediate medical evaluation, usually through a hos-
pital Emergency Department or immediate contact with the
ICD clinic (if possible).
(2) Assessment in the Emergency
Department or ambulance setting
† Cardiac arrest:
Deliver advanced cardiac life support according to guidelines,
independent of the fact that the patient has an ICD implanted.
† ECG:
Establish continuous ECG monitoring as soon as possible. Try
to record a 12-lead ECG during tachycardia and normal
rhythm, which provides crucial information for further assess-
ment of the arrhythmia.
† Clinical assessment:
Assessment of patient’s history (underlying heart disease,
primary/secondary prevention indication, history of previous
shocks, drug therapy, etc.) haemodynamics (blood pressure,
signs of low cardiac output) and ischaemia. Echocardiography
or another imaging technique of cardiac function should be per-
formed as soon as possible. Ask for patient symptoms preceding
or following the shock (syncope, dizziness palpitations, chest
pain, dyspnoea, etc.) and situational circumstances (rest, exer-
cise, arm movement, potential exposure to electromagnetic
interference, etc.).
† Contact the ICD clinic:
A clear algorithm should be in place in the emergency depart-
ment regarding how to establish contact with the ICD clinic.
† Ongoing tachyarrhythmia (ventricular or atrial) with
haemodynamic compromise:
Treat arrhythmia independently of the presence of the ICD.
Consider external DC shock, iv administration of amiodarone
and /or b-blockers (if haemodynamically tolerated). For exter-
nal DC shock, avoid placement of paddles in the skin area
over the ICD pocket. When possible, attempt an anterior–pos-
terior electrode position.
† Tachyarrhythmia (ventricular or atrial) without haemo-
dynamic compromise:
Treat the arrhythmia with drugs. Consider consulting the ICD
specialist for ICD reprogramming and/or delivery of ATP.
† Repetitive ICD shocks in the absence of tachyarrhythmia or
due to tachyarrhythmia (atrial or ventricular) that is hae-
modynamically well tolerated by the patient:
Place a magnet over the device to inhibit further shock delivery
(Figure 2). For this purpose, the pacemaker manufacturers
provide special magnets of sufficient size that should be readily
available in ambulance cars, emergency departments, and cardiol-
ogy wards. These magnets can be used in an emergency setting
regardless of the device type or the manufacturer. Magnet place-
ment temporarily disables tachyarrhythmia therapies by affecting
a reed switch in the device circuit. If constant inhibition of
tachyarrhythmia therapies is desired, the magnet should be
secured with tape. During magnet mode, it is mandatory to main-
tain continuous ECG monitoring in order to detect potentially
life-threatening ventricular tachyarrhythmias. In contrast to pace-
makers, magnet application over an ICD does not change the
mode of pacing. A detailed review of the responses of currently
available ICDs to a magnet is reported in Table 2. With very few
exceptions, the ICD will resume the ability to deliver therapy for
ventricular tachyarrhythmias as soon as the magnet is removed
(Table 2).
† Repetitive delivery of ICD shocks due to ineffective ICD
therapies or immediate tachyarrhythmia re-initiation
after shock:
See the section ‘Electrical storm’. Institute appropriate drug
therapy (sedatives, b-blockers, amiodarone). Consider deep
sedation or general anaesthesia. If haemodynamically well toler-
ated, consider magnet placement to prevent further shock deliv-
ery. Consult ICD specialist concerning ICD reprogramming and
further treatment.
† Laboratory assessments:
Electrolytes (potassium, magnesium) should always be checked
and imbalances should be corrected. Tests for myocardial
ischaemia, heart failure (BNP), renal function, respiratory insuf-
ficiency, pH, drug intoxication (e.g. digoxin, barbiturates, etc.),
Figure 2 Placement of magnet. A pacemaker magnet is placed
and fixated over the ICD device. During magnet placement,
tachycardia treatments are inhibited while pacemaker functions
are preserved. See also Table 2.










or drug addiction (e.g. cocaine) should be performed if clinically
indicated.
† Skin contact with the patient during ICD discharge:
This involves no immediate danger; however, the use of gloves
(single or double) decreases conductivity and attenuates poten-
tial discomfort.17
† Audible device alert:
Ask if the patient recently perceived audible alerts from the
device possibly indicating battery exhaustion, abnormalities in
lead impedance, or other device-related or clinical problems.
(3) Device-related recommendations in
the acute setting
† Programmer:
Ensure ECG monitoring and device interrogation with real-time
telemetry. If unknown, the ICD device type can be identified on
the patient identification card in order to select the specific
device programmer.
† Device interrogation:
– Analyse ICD detections, delivered therapy reports, and
stored electrograms in order to assess the appropriateness
of therapies.
– Re-evaluate tachyarrhythmia settings (detection zones, pro-
grammed therapies)
– Pay particular attention to warnings for low battery voltage,
device life time, charging time of the capacitors, and shock
impedance (normal value: 20–100 V).
– Check shock impedance and its change compared with pre-
vious assessments.
– Assess pacing-lead impedance (normal value: 200–1000 V).
A significant increase may indicate micro-/macro-lead dis-
lodgment, lead fracture, or altered connection to pulse gen-
erator or adapters, fibrosis at lead-myocardial interface,
change in myocardial substrate (infarct in the area surround-
ing lead tip), or adverse pharmacological effects; a significant
decrease in pacing impedance suggests lead or adaptor insu-
lation failure.
– Assess capture thresholds and sensing of R and P-waves in
comparison to previous assessments.
– If oversensing due to lead or adaptor failure or myopotentials
is suspected, consider provocative manoeuvres (adduction,
abduction of the arm, Valsalva manoeuvre, manipulation of
the pocket, etc.) during real-time telemetry of near- and far-
field electrograms with marker channels, after inactivation of
therapy delivery.
– If lead dislodgement, altered connection of lead(s) or
adaptor(s) to the device, insulation defect due to subclavian
crush syndrome, or Twiddler’s syndrome is suspected a chest
radiography should be performed.
(4) Assessment of acute stress
Receiving one or multiple shocks can cause acute stress reactions.
These can potentially lower the threshold for repeated arrhyth-
mias by causing an imbalance in sympathetic and parasympathetic
tone and, in a subgroup of patients, lead to anxiety disorders,
post-traumatic stress, depression, and other forms of psychological
maladaptation. Psychological reactions to the event should there-
fore be assessed in the acute setting:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Response to magnet of currently available ICDs from various manufacturers
Manufacturer Response to magnet
Tachyarrhythmia therapies Bradycardia therapies Confirmation
Boston
(Guidant/CPI)
Inhibition of detection and therapy delivery for VT/
VF, lasting as long as the magnet is positioned
over the ICD; if the ‘change tachy mode with
magnet’ function is enabled (currently not a
default programming), magnet application for
more than 30 s results in deactivation of the
device (the ICD remains inactive when the
magnet is removed)
As programmed R-wave synchronous beeping tones are emitted
by the device if it is active, whereas a
continuous tone is emitted if the device is
inactive (these functions are currently the
default programming)
Medtronic Transient inhibition of detection and therapy
delivery for VT/VF, lasting as long as the magnet
is positioned over the ICD
As programmed No confirmation
St Jude Medical Transient inhibition of detection and therapy
delivery for VT/VF, lasting as long as the magnet
is positioned over the ICD
As programmed No confirmation
Sorin Transient inhibition of detection and therapy
delivery for VT/VF, lasting as long as the magnet
is positioned over the ICD
Pacing at magnet rate in the
programmed pacing
mode (VVI, DDD, DDI)
No confirmation
Biotronik Transient inhibition of detection and therapy
delivery for VT/VF, lasting as long as the magnet
is positioned over the ICD
As programmed No confirmation
Modified from Pinski.110










– Ask patients for his/her perception and interpretation of the
shock. Misconceptions sometimes occur and can impair psycho-
logical adjustment.
– Ask for feelings of anxiety, helplessness, or panic.
– Ask for sources of support in the family, friendship, etc., as well
as in the medical system (support from general practitioner,
ongoing psychotherapy, etc.).
If relevant distress is encountered, basic interventions should be
offered in order to stabilize the patient. These can include:
– Provision of reassurance by empathetic listening, correction of
misbeliefs about the shock and/or arrhythmia, or help with
calling friends or relatives for emotional support. If patients
feel traumatized by the shock, physical and emotional security
is their most urgent need and can help prevent the develop-
ment of severe post-traumatic stress disorders.
– Benzodiazepines may be used for reducing acute anxiety, in par-
ticular if distress is considered relevant for triggering repeated
arrhythmias.18
– If needed, consultation of a mental health expert (Psychoso-
matic Medicine, Psychology, or Psychiatry) for assistance in
the judgement of the acute distress and the need for acute
treatment.
Electrical storm
Electrical storm is defined as the occurrence of three or more dis-
tinct episodes of VT and/or VF within a 24-h period, either result-
ing in a device intervention or monitored as a sustained VT
(≥30 s).18– 20 Some authors have set an arbitrary 5 min interval
between VT/VF episodes to define ES.20 Treatment recommen-
dations for repetitive ICD shocks in the absence of tachyarrhyth-
mia, e.g. due to device malfunction, are provided in the previous
section.
Incidence, triggers, and substrates
Electrical storm has been reported in 10–40% of patients in sec-
ondary prevention,19,21 –23 whereas the incidence of ES is lower
in primary prevention.24 Electrical storm results from a complex
interplay between arrhythmogenic substrates and acute pertur-
bations in autonomic tone and cellular milieu.25 No independent
predictors have been reproducibly identified.21,22 Potential trigger-
ing factors include modification of or non-compliance to drug
therapy, worsening of heart failure, early postoperative period,
emotional stress and anger, alcohol excess, electrolyte abnormal-
ities, and myocardial ischaemia. However, most cases of ES
occur without any apparent cause.19,22,23,26 It is predominantly
caused (more than 80%) by episodes of monomorphic VT.19–23
Nevertheless, it can also occur due to polymorphic VT/VF,
especially in the context of myocardial ischaemia. Knowledge of




Whenever a reversible cause can be identified such as drug
side effects, electrolyte disturbances, or myocardial ischaemia,
measures should be undertaken for its rapid correction.
Drugs
– A reduction in sympathetic tone by b-blockers and sedation are
essential as increased sympathetic activity plays a key role in the
genesis of ES.27 When imminent haemodynamic instability is a
threat, intravenous administration of short acting agents, such
as esmolol, may be considered.
– Class III antiarrhythmic agents such as intravenous amiodar-
one28 or sotalol29 can be effective. Amiodarone combined
with a b-blocker appears to be more effective than sotalol or
b-blocker alone.25 Class I antiarrhythmic drugs should generally
be avoided. However, procainamide, flecainide, and quinidine
have been used successfully in some ICD patients. Lidocaine
could have some beneficial effect, especially if ES is associated
with acute ischaemia. The combination of antiarrhythmic
agents with different mechanisms of action (e.g. amiodarone
and lidocaine) may prove effective in some cases. Some
genetic disorders may require specific treatment. For
example, in the Brugada syndrome, quinidine or isoproterenol
may terminate incessant arrhythmias. More detailed information
on the treatment of ventricular arrhythmia is provided in the
specific guidelines.2
Importantly, the use of most antiarrhythmic drugs (especially amio-
darone and procainamide) may cause an increased cycle length of
the arrhythmia. As a result, the rate of the arrhythmia may drop
below the detection cut-off, thus requiring adjustments of the
device settings.
Polymorphic ventricular tachycardia
In polymorphic VTs such as torsades de pointes, intravenous
administration of magnesium sulphate, potassium, and overdrive
pacing (e.g. at 90 bpm or more) may be effective in suppressing
the re-initiation of polymorphic VT. In ES patients with inherited
or drug-induced long QT syndrome, isoproterenol may
prevent recurrent episodes of arrhythmia. b-Blockers and revascu-
larization are indicated in polymorphic VT triggered by myocardial
ischaemia.
Catheter ablation
Catheter ablation has developed into a successful treatment strat-
egy for ES with acceptable safety.30 Although it is predominantly
used for recurrent or incessant monomorphic VTs, it can also
be considered in polymorphic VT/VF triggered by ectopic
foci31,32 (see also section below).
Anaesthesia and other measures
If the above strategies fail, general anaesthesia or thoracic epidural
anaesthesia can be considered.33,34 Mechanical circulatory support
can be an alternative as a bridge to cardiac transplant or tempor-
arily for stabilization and subsequent catheter ablation.35











The general assessment of an ICD patient after shock(s) always
includes a thorough evaluation of underlying heart disease, in par-
ticular the assessment of myocardial ischaemia and heart failure.
Potential triggering factors should be identified, such as electrolyte
derangements, medications prolonging the QT interval, and/or
potential intercurrent illnesses, e.g. infection that may provoke
increased arrhythmic activity. The possibility of drug non-
compliance or recent medication changes should be considered.
For example, electrolyte abnormalities secondary to the use of
diuretics or to angiotensin converting enzyme inhibitors are not
uncommon. This is particularly relevant to heart failure patients,
a substantial proportion of which have concomitant renal failure.
Ischaemia
As ischaemic heart disease is the principal diagnosis in the majority
of ICD patients, it is essential to recognize the possibility of myo-
cardial ischaemia as a trigger of ventricular arrhythmias.36–38 Since
patients may have atypical symptoms and the 12-lead ECG may not
be reliable (especially immediately after an ICD shock or in patients
who are paced), acute coronary syndromes need to be excluded
by means of cardiac enzyme measurements.
However, it should be noted that troponin level elevations are
commonly observed after episodes of sustained VT, in cardiac
arrest survivors and after ICD shocks. In many cases, such bio-
marker increase rather reflects global myocardial oxygen depri-
vation during arrhythmia than a local obstruction of coronary
flow. Therefore, the diagnosis of ‘myocardial infarction’ with a con-
comitant ventricular arrhythmia should be made only after a
careful diagnostic work-up. Coronary angiography (in comparison
with previous findings, if available) may be necessary in selected
patients. If an acute coronary event is ruled out, exercise stress
testing in combination with appropriate cardiac imaging should
be performed.
If ischaemia is considered to play a role, revascularization may be
necessary and has been demonstrated to reduce arrhythmia recur-
rences.38 The CABG-Patch trial showed a low incidence of ventri-
cular arrhythmias requiring a defibrillator shock, in patients with
decreased systolic function and a substrate for VT, subjected to
CABG. This may, in part, depend on a protective effect of revascu-
larization with suppression of ischaemia-mediated VT.39 However,
in other studies, post-MI patients with previous VT/VF remained at
high risk for VT/VF even after revascularization.40,41 Ventricular
tachycardia substrates originating from border zones between
scar tissue and normal myocardium may be refractory to pharma-
cological treatment and are often the source of frequent ICD
shocks or ES. In these cases, catheter ablation may be indicated42
(see the section below).
Heart failure
The majority of ICD patients suffer from chronic heart failure and
deteriorating heart failure may trigger supraventricular and ventri-
cular tachyarrhythmia. In primary prevention patients, both appro-
priate and inappropriate ICD shocks are associated with an
increased risk for death, in particular death from heart
failure.7,8,43 Therefore, device shocks should raise attention as to
the possibility of disease progression and a careful assessment of
the patient’s heart failure status and optimization of therapy, in par-
ticular with regard to b-blockers, should be performed.36,43
In ICD patients without CRT, it is important to avoid unnecess-
ary RV pacing,44,45 whereas the percentage of biventricular stimu-
lation should be as high as possible in those with CRT-D. If poor
rate control during AF causes insufficient CRT delivery,
AV-junctional ablation should be considered.46 Although not yet
supported by clinical outcome trials, optimization of programma-
ble pacemaker parameters should be suggested in patients with
refractory symptoms of heart failure after CRT implantation.
Heart failure management may also be improved by using the diag-
nostic information from device-based diagnostic features such as
monitoring of intrathoracic impedance, heart rate, heart rate varia-
bility, and physical activity.47
Driving
Once a patient has received one or more device shocks, it is
important to provide adequate advise about the pertaining
driving regulations. A newly published EHRA consensus statement
provides guidance in this area.48 Notably, there may also be
national guidelines that apply. Usually, a delivered ICD shock impli-
cates that the patient is excluded from driving a car for a period
and/or may be permanently excluded for driving certain vehicles
according to the national laws. Owing to legal aspects, it is manda-
tory to make a note in the patient’s record about the information
provided.
Treatment termination
In an end-of-life situation, ICD therapies can be deactivated equiv-
alent to a ‘do not resuscitate order’ taking individual circumstances
with regard to the quality-of-life-impact by the device, the
expected survival and the futility of therapy into consideration.
The decision may differentiate between deactivation of shock
therapies and ATP algorithms. In a joint consensus document,
EHRA together with the HRS provide helpful direction in the
field.49 A European perspective to this statement will follow
shortly. Further advice can be found in the literature.50– 52 It is
prudent that patients and kin are informed about the possibility
of discontinuing ICD therapies early on in the course of treatment
to elaborate a competent view on this complex subject.
Drug therapy
Chronic treatment with various drugs, ‘antiarrhythmics’ and
others, can prevent ICD shocks by suppressing ventricular tachyar-
rhythmia or slowing rapid VTs to make them amenable to success-
ful ATP. However, it remains to be proven whether the prevention
of ICD shocks by drug therapy also improves the prognosis of ICD
patients.
b-Blockers
b-Blockers prolong life in patients with heart failure and survivors
of myocardial infarction. Furthermore, they convey some protec-
tion against sudden death53 and their proarrhythmic potential is
low. Therefore, b-blockers are the first-line choice to reduce epi-
sodes of atrial and ventricular arrhythmias or to slow the










ventricular rate during supraventricular arrhythmias in ICD
patients. Despite this, the effectiveness of b-blockade to reduce
SCD in ICD patients has been disputed54,55 and many patients
will still experience shocks necessitating the prescription of
additional antiarrhythmic agents.
Amiodarone
According to a recent meta-analysis in patients without ICD, amio-
darone decreases the risk of SCD and cardiovascular death by 29
and 18%, respectively.56 However, amiodarone has no effect on all-
cause mortality and is associated with a two- and a five-fold
increased risk of pulmonary and thyroid toxicity.
Observational studies and randomized clinical trials showed that
amiodarone is effective in reducing the number of ICD shocks by a
variable extent.57,58 A combination with a b-blocking agent proved
more effective than b-blocker alone or compared with sotalol.58
However, these positive effects should be balanced against the
increased risk of drug-related adverse effects. In addition, the
possibility of an increase in the defibrillation threshold under amio-
darone has to be kept in mind. However, data from modern bipha-
sic endovascular devices do not suggest a clinical relevance of this
potential adverse effect.59
Sotalol
In a randomized multicentre trial,29 sotalol significantly reduced the
combined endpoint of all-cause mortality or first appropriate ICD
shock by 44%. These findings were corroborated in a smaller pro-
spective study in patients with ICD for secondary prevention.59 In
the OPTIC study, sotalol tended to reduce shocks compared with
b-blockers but was significantly inferior to amiodarone. Thus,
sotalol is a valid option for ICD shock prevention and can be con-
sidered on an individual patient basis, in particular if amiodarone is
contraindicated.
In selected cases, also the use of class IA or IC drugs may be jus-
tified and special recommendations may apply for patients with
genetic disorders such as the Brugada syndrome. Detailed advice
concerning the long-term drug treatment of ventricular arrhythmia
has been published elsewhere.2
Upstream therapy
Apart from specific antiarrhythmics, other drugs can contribute to
lower the risk for ventricular tachyarrhythmia and ICD shocks.
Angiotensin converting enzyme inhibitors given in appropriate
doses60 and statins61 can reduce the atrial and the ventricular
arrhythmia burden as shown in retrospective trial analyses. The
role of statins has also been assessed in ICD patient cohorts
from MADIT-II and DEFINITE,62,63 confirming a significant
decrease in unnecessary ICD therapies associated with statin use
in patients with either ischaemic or nonischaemic heart failure
aetiology. Aldosterone blockers have shown to be effective in
the primary prevention of SCD in high-risk individuals with systolic
left ventricular dysfunction64,65 and may be effective as an adjunct
to ICDs and/or CRT, both in the primary and the secondary pre-
vention of SCD.66,67
Device programming
Implantable cardiac defibrillators can terminate ventricular tachyar-
rhythmias either by ATP or delivery of electrical shocks.7,68,69 Anti-
tachycardia pacing is preferred if possible, and all efforts should be
made to avert inappropriate shock therapies because they cause
patient discomfort are potentially proarrhythmic and decrease
battery life. In fact, clinical studies confirmed that ATP and strategic
ICD programming are effective and safe in reducing the number of
shocks and improving the quality of life.70,71 This section provides
recommendations for the programming of ICD devices aiming to
reduce the number of unnecessary and inappropriate shock thera-
pies. It is important to point out that programming of devices
always needs to be adjusted to the individual patient.
Minimizing unnecessary shocks
Ventricular tachycardia and ventricular fibrillation
detection zones
Up to three ventricular rate-detection zones can be programmed
to allow delivery of different ICD therapies depending on the rate
of ventricular tachyarrhythmia. In patients with structural heart
disease, recent studies have shown that it is useful to set upper
boundary for slower VT around 188 bpm (320 ms), zone for fast
VT between 188 and 250 bpm (320–240 ms), and VF zone from
200 bpm on.70– 72 These studies demonstrated high effectiveness
of ATP in terminating both slow and fast VTs. There is solid evi-
dence that ATP is equally effective in termination of fast VTs in sec-
ondary as well as in primary prevention patients. In primary
prevention, programming a slow VT monitor zone can be helpful
to detect other than fast ventricular tachyarrhythmias. In patients
without structural heart disease (e.g. patients with genetic dis-
orders), VT zones should be adapted to the expected higher
heart rates reached during exercise, in particular in younger
patients.
Antitachycardia pacing
Optimization of ATP is the most effective strategy to reduce
appropriate shocks.70,73 In the Pain-free-RX II study,70 a VT zone
from 188 to 250 bpm was programmed and patients were ran-
domized to receive one sequence of eight ATP pulses at 88% of
the tachycardia cycle length followed by shock therapy, if necess-
ary, or an immediate shock. In the ATP group, 81% of fast VTs
could be terminated successfully by ATP only. This reduced defi-
brillator shocks and translated into a significantly better quality
of life. These findings were further corroborated by the results
of other studies.71,72,74
ATP interventions are based on trains of pacing impulses with an
equal (burst) or decrementing (ramp) interstimulus interval.
Studies investigating the relative efficacy of these two ATP patterns
showed similar effects regarding VT termination.75,76 However, in
fast VTs (cycle length ,300 ms), burst pacing is more likely to ter-
minate the tachycardia than ramp pacing.72 ATP efficacy also
depends on a sufficient number of attempts and duration of
pacing trains that can be programmed according to the patient’s
haemodynamic tolerance during VT episodes. The underlying left
ventricular function is an important parameter in this respect.77
In patients with fast VT, a maximum of two ATP attempts is










Figure 3 (A) Appropriate ICD discharge. Fast VT is detected and a successful shock delivered (arrow). (B) Inappropriate ICD discharge. Fast
ventricular rate caused by AF is detected in the VT zone (see marker ‘Ts’) triggering an inappropriate shock delivery. The device has only a
ventricular lead making the discrimination between AF and VT difficult. Irregular and short cycle lengths are typical for fast conducted AF
(see numbers below annotations). Atrial fibrillation persists, however, with a transiently slower AV conduction. (C) T-wave oversensing. Inap-
propriate shock caused by T-wave oversensing. In the marker channel (on the top), correct sensing of QRS complexes (Vs) is followed by
sensing of T-waves (VF). Ventricular signals have a higher amplitude compared with smaller T-wave signals (lower channel). (D) Artefacts,
lead fracture. Inappropriate shock therapy in a patient with lead fracture. Oversensing of noise in the intracardiac electrograms (arrow). In
the marker channel (bottom), non-physiological short intervals (,200 ms) are registered (see numbers below annotations).










commonly recommended. Each sequence typically consists of 8
beats; however, 15 beats were documented equally effective and
even preferable in the subgroup of secondary prevention subjects
with preserved left ventricular ejection fraction.78 Strategic ATP
programming can be performed empirically with preset par-
ameters and such approach is not inferior to tailored ATP
programming.72
Time to detection and therapy
Studies also showed that it is important to increase the time to
detection and therapy to allow spontaneous termination of non-
sustained ventricular arrhythmias. It may vary from 16/18 to 30/
40 beats without compromising safety.71,79 Painless termination
of fast VTs by ATP is associated with a significant improvement
in quality of life. Still, in patients with haemodynamically compro-
mising VTs, immediate ‘shock therapy’ may be required to termi-
nate the arrhythmia quickly.
Minimizing inappropriate shocks
There are two main causes of inappropriate shocks: supraventricu-
lar arrhythmias and device dysfunction. Inappropriate therapy
delivery is most frequently triggered by atrial arrhythmias, usually
Figure 3 Continued.










AF (Figure 3B), resulting in high ventricular rates. This may be pre-
vented by adequate rate control therapy with AV-nodal slowing
agents, usually b-blockers or (in patients without heart failure)
non-dihydropyridine calcium channel blockers in combination
with digitalis glycosides. In refractory patients, amiodarone or dro-
nedarone can be effective in lowering the ventricular response
rate. Especially in patients receiving CRT, ablation of the
AV-nodal conduction should be considered. In some patients,
rhythm control therapy may be preferred80 either with pharmaco-
logical treatment or, in selected patients, using pulmonary vein
ablation. If atrial flutter, AVNRT, AVRT, or other supraventricular
tachyarrhythmias are the cause for inappropriate shocks, catheter
ablation should be considered. In cases of inappropriate shocks
due to sinus tachycardia, increased b-blockade usually suffices,
whereas the addition of non-dihydropyridine calcium channel
blockers may be occasionally necessary in selected patients
without heart failure.
In addition, ICD devices offer a variety of algorithms for the dis-
crimination between SVT and VT aiming to withhold
therapy delivery. These vary between single- and dual-chamber
devices. Dual-chamber ICDs take advantage of atrial sensing
capabilities to enhance discrimination between SVT and VT. Single-
chamber devices have limited capabilities for arrhythmia discrimi-
nation81 and largely rely on sudden onset or stability criteria.
Recently, morphology criteria are more commonly used in
addition.
Accordingly, appropriate programming of these tools may help
to reduce the number of inappropriate ICD therapies. Table 3 sum-
marizes the discrimination algorithms commonly implemented in
current ICDs, and Table 4 shows causes of inappropriate shock
delivery due to signal misinterpretation and provides solution
strategies. Figure 3A–D gives typical examples for appropriate
and inappropriate shock delivery.
Device-related causes of arrhythmia
When analysing the cause of ventricular arrhythmias leading to
ICD therapies, clinicians should be aware of several mechanisms
by which failure but also ordinary operation of the device may
provoke arrhythmia.82 As described in Table 4 and Figure 3D,
lead failure and connector-block issues are a frequent cause of
inappropriate therapies. Furthermore, the delivery of ATP or inap-
propriate shocks may trigger the onset of malign arrhythmia.
Additionally, short–long–short sequences facilitated by bradycar-
dia pacing might constitute an important mechanism of device-
related ventricular proarrhythmia.83 Although a rare event, the
possibility of pacing-related monomorphic and polymorphic VTs
in patients receiving CRT, the latter possibly resulting from an
increased dispersion of refractoriness and heterogeneity in con-
duction patterns, should be ruled out.84 Finally, lead dislodgement
or local lead effects with mechanical irritation and late fibrosis may
be a potential mechanism for VT.83 Therefore, cardiac imaging
should be performed to exclude mechanically induced VT/VF
especially in the early period after implant.
Catheter ablation
Although antiarrhythmic drugs may reduce recurrence rates of
VTs and ICD shocks, their use is often limited by decreased effi-
cacy and significant side effects.58,85 Over the past two decades,
the understanding of ventricular arrhythmogenic substrates and
electrophysiological techniques and tools for their ablation have
been greatly improved. As a result, catheter ablation of VTs is
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Table 3 Algorithms for discrimination of atrial tachycardia and VT
Algorithm Principle algorithm Comment
SVT detection Compares atrial and ventricular rates before further
discrimination criteria are applied (dual-chamber ICDs)
Possible outcomes are that atrial and ventricular rates are equal
(A ¼ V), atrial rate is faster (A . V), or vice versa (V . A). In
the case of V . A, the diagnosis is VT. If A ¼ V, additional
criteria are required for discrimination
Sudden onset (SO) The SO criterion is fulfilled if the RR interval shortens by a
programmed percentage when compared with the
average number of preceding beats
Allows discrimination of gradually accelerating sinus tachycardia
from suddenly occurring VT. May fail if VT occurs during sinus
tachycardia (e.g. exercise) with a small decrease in RR interval
Rate stability (RS) RS is expressed as %deviation between RR intervals Confirms AF. However, AF with pseudo-regular ventricular
rhythm and irregular VTs can be falsely classified as VT or SVT,
respectively, which may cause delivery of inappropriate therapy
or delay of appropriate therapy
Sustained rate
duration (SRD)
Initiates shock delivery after a programmable time interval
(e.g. 1 min) even if the episode has been classified as SVT
Aims to prevent that VT therapies are erroneously inhibited by
sudden onset and stability criteria. SRD may cause
inappropriate shocks. Activation should be avoided, if possible,




Based on the comparison of intracardiac electrograms in
sinus rhythm and during VT111
Composes templates of electrogram morphology during normal
rhythm that is expected to differ from that registered during
ventricular arrhythmia. Especially useful in single-chamber
devices due to the lack of atrial lead information. MD algorithms
should not be activated in patients with bundle branch block or
rate-dependent electrogram changes










today considered earlier in the management of patients with recur-
rent VTs.13,30
Strategies to ablate VTs in patients with different morphological
substrates have been discussed in detail in other documents.42
Principally, the mechanism of VT determines the selection of an
appropriate mapping strategy to identify target sites for catheter
ablation. A 12-lead electrocardiogram of the clinical VT is essential
to document the morphology. If not available, the VT cycle length
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False-positive arrhythmia detection. ICD misclassifies
T-wave as R-wave
Common cause of inappropriate shocks112 often in the setting
of low sensing thresholds due to low-amplitude R-waves.
Can be addressed by (i) decreased ventricular sensing
(sensing of low-amplitude VF must be enabled), (ii)
lengthening of the refractory period to suppress T-wave
detection (may limit the detection of VT), (iii) changing
sensing decay parameters (not available in all devices).
Nevertheless, lead revision is often required. A true bipolar
defibrillation lead may be preferred compared with





Owing to electromagnetic radiation from external sources.
EMIs can be misinterpreted by the ICD as intracardiac
signals resulting in electrical shocks and/or withhold of
pacing
Household appliances (microwave oven, portable telephone,
personal computers, etc.) do not interfere with modern
ICDs. Cellular phones should be held on opposite side and
close contact with the device should be avoided.114
Electromagnetic sources potentially interfering with
(especially older generation) ICDs are electronic article
surveillance devices, metal detectors, improperly grounded
appliances held in close contact to the body, high-voltage
power lines, transformers, welders, electric motors,
induction furnaces, degaussing coils, MRI scanners,
electrocautery during surgery, defibrillation,
neuro-stimulators, TENS units, radiofrequency catheter
ablation, therapeutic diathermy, radiotherapy, and
lithotripsy. Very strong EMI fields may reset the ICD to a




Includes lead fracture, lead insulation failure, conductor coil
fracture, and loose set screws
Frequent cause of inappropriate shocks. Lead fracture usually
causes high lead impedance (1000–2000 V) and outer
insulation failure low impedance. Inner insulation failure
allows the two conductor coils to communicate. A
conductor coil exposed to skeletal muscle may cause
inappropriate shock due to oversensing (Figure 3D).
Can be revealed by an analysis of intracardiac electrograms
and event markers (oversensing, non-physiological short
intervals ,150 ms). Modern ICDs provide alert features for
lead integrity. Remote device monitoring is helpful to
identify malfunction early. Reprogramming the ICD is usually
not sufficient and replacement or reconnection of the lead is
necessary. Insertion of a sensing/pacing lead may be
considered
Double or triple sensing
of ventricular signals
Can occur in patients with wide ventricular complex May be prevented by changing the sensing decay algorithm,
lengthening of the refractory period, or lowering of the
sensitivity. Newer devices allow for increasing the blanking
period
Myopotentials Detection of pectoral myopotentials Very uncommon. Has been reported due to reversal of the
proximal and distal coil in the header. Oversensing of
diaphragmatic myopotentials occurs more frequently with
integrated bipolar leads. Decreasing the sensitivity is the
initial step. Repositioning of the lead or implantation of a
true bipolar lead may be required
Double tachycardias Atrial and ventricular arrhythmias exist at the same time May result in withholding therapy, e.g. if AF is sensed at a higher
rate than concomitant VT. Morphology criteria may help to
discriminate SVT vs. VT










from stored intracardiac electrograms may be the only available
information. In these patients, substrate identification using elec-
trophysiological mapping techniques and voltage criteria may
enable substrate modification to suppress all inducible VTs. After
an acutely successful ablation procedure, long-term recurrences
may still occur and most patients with structural heart disease
will continue to have a standard indication for ICD therapy.
More recently, the concept of prophylactic catheter ablation of
VT in post-myocardial infarction patients with a secondary ICD
indication has been introduced.13,14 However, the results of
larger studies should be awaited before prophylactic ablation can
be recommended.
It has to be emphasized that catheter ablation of ventricular
arrhythmias in structural heart disease requires special training
and should be reserved for expert centres.
Catheter ablation of ventricular
tachycardia is recommended
(1) For symptomatic sustained monomorphic VT necessitating fre-
quent ICD therapies despite antiarrhythmic drug therapy or
when antiarrhythmic drugs are not tolerated or not desired
(especially when VT recurrences fulfil definition of ES).
(2) For control of recurrent symptomatic or incessant monomor-
phic VT not suppressible by antiarrhythmic drug therapy,
regardless whether VT is stable or unstable, or multiple VTs
are present.
(3) For bundle branch re-entrant or interfascicular VTs.
(4) For recurrent sustained polymorphic VT and VF refractory to
antiarrhythmic therapy when there is a suspected trigger that
can be targeted by ablation.
Ventricular tachycardia catheter ablation
is contraindicated
(1) In the presence of a mobile ventricular thrombus, epicardial
ablation may be considered.
(2) For VT due to transient, reversible causes, such as acute
ischaemia, hyperkalaemia, or drug-induced torsades de
pointes.
Long-term follow-up
Patient education and counselling are important components of an
integral follow-up strategy and mandatory for the overall success
of ICD therapy. This applies in particular to patients having
received shocks. Recent guidelines recommend in-office follow-up
visits within 72 h and again 2–12 weeks after implant, followed by
regular in-office or remote follow-up visits every 3–6 months.49
However, patients with a recent shock event may require intensi-
fied in-office or remote follow-up in order to evaluate the clinical
course of the arrhythmia, the underlying heart disease and the
response to drug therapy or other interventions.
In-office follow-up
Apart from the technical device assessment, in-office follow-up
visits offer the important opportunity to provide oral and
written information. The ICD patient and his family should have
a basic understanding of the technical aspects of treatment as
well as a realistic expectation about its capabilities and limitations.
It is prudent to discuss the potential scenario of shock delivery and
to provide information how to act in such situation.
Remote follow-up
Remote monitoring is being increasingly used in ICD follow-up and
offers the continuous surveillance of technical device performance
and diagnostic information stored by the device.16,86 With last gen-
eration technology, sustained or self-limited VTs and delivered
therapies can be notified by automatic wireless data transmission
to a central server or service centre that forwards an alert to
the clinical staff by e-mail or short messages service (sms). The
clinician can then evaluate episode details on a website. In non-
wireless devices, patients may manually send the data and inform
the ICD clinic by phone about the transmission in the case of sig-
nificant events. This allows a prompt evaluation of the appropriate-
ness of detection and effectiveness of delivered therapy. If device
function is deemed appropriate and clinical status is stable, the
patient can be reassured and further follow-up scheduled. In the
opposite case, patients can be directed to a hospital or the ICD
clinic. Remote monitoring can also alert on clinical or
device-related issues that are associated with an increased risk
for appropriate or inappropriate shock delivery, e.g. recurrent self-
limited VT, AF with high ventricular heart rate response, lead
failure among other things.87 Timely treatment of such conditions
may prevent clinical deterioration and/or subsequent shock
therapies.
In an Italian multicentre study using the non-wireless CareLinkTM
Network system,88 81% of ventricular tachyarrhythmia episodes
could be analysed remotely, and in 85% of them, no further
action was needed. The HRS recommends that the cardiac
rhythm management device manufacturers develop and utilize
wireless and remote monitoring technologies to identify abnormal
device behaviour as early as possible and to reduce under-
reporting of device malfunction.89
Remote monitoring has been introduced as a standard clinical
practice in a recent expert consensus49 stating that it can replace
standard in-office visits. In-office visits, however, are recommended





Implantable cardiac defibrillator therapy is generally well accepted
by patients and, on average, associated with preserved or improved
quality of life when compared with antiarrhythmic treatment.90–92
However, a subgroup has difficulty adjusting to the new demands
of living with the heart disease itself and the ICD, with approxi-
mately one-third of ICD patients experiencing anxiety and
depression.12 Anxiety is the most important psychological side
effect of ICD therapy, attributable to the device being able to
provide an uncontrollable shock.12,93 The level of psychological
distress varies in severity, ranging from low (normal) levels of










distress to severe disorder12 such as post-traumatic stress dis-
order.94 Levels of anxiety and depression generally decrease
during the first year following implantation, indicating that patients
adapt to ICD therapy over time.93 However, if anxiety is present at
the time of implantation, it may persist up till 12 months in as many
as 50% of patients.95
The vicious cycle of shocks, psychological
distress, and health outcomes
Data from observational studies and clinical trials show that the
experience of ICD shocks is linked to poor psychological and
quality of life outcomes, although the evidence supporting the
impact of shocks on these outcomes is not consistent.92,96 The
appropriateness and the number of shocks may also have a differ-
ential impact on patient distress and device acceptance. Awareness
of having received inappropriate therapy and/or an ES may com-
promise patient trust in the device, and increase levels of psycho-
logical distress.97 A continuum of the type of ICD therapy, how
patients cope with the therapy, and the associated distress, feelings,
and thoughts are presented in Table 5.
Not only the actual ICD shock but also the fear of shock incurs
an increased risk of distress98 in particular in patients with a
specific psychological profile—such as the distressed (Type D) per-
sonality.93 This emphasizes the importance of taking the psycho-
logical profile of the patient into account, including factors such
as Type D personality,99 depressive coping,100 and lack of opti-
mism.101 The presence of one or more of these factors has
been shown to be at least as important as the event of an ICD
shock itself in predicting adjustment problems of ICD patients.
Patients with a high-risk psychological profile may have a tendency
to interpret ICD shocks as malignant, suggesting that it is not the
actual shock that leads to distress but more the patient appraisal
and interpretation of the shock.12 Importantly, the manifestation
of psychological distress may lead to avoidance behaviours, a
sedentary lifestyle, sexual problems, and poor quality of life,12
but also to an increased risk of life-threatening arrhythmias102,103
and mortality in ICD patients.94,104 Therefore, breaking this
vicious circle as hypothesized in Figure 4, which also summarizes
the underlying physiological mechanisms, is important.
Preventive measures
One way of breaking this vicious cycle is to prevent the manifestation
of anxiety and depression. This can be facilitated by reducing shock
rates and by supporting the patients’ coping resources. Therefore,
psychological symptoms and maladaptive personality traits or
coping strategies should be identified as early in the course of
disease as possible, preferably even before ICD implantation. In clinical
practice, this can be done by means of asking the patient to complete a
self-report measure, with our recommendation of a list of such
measures provided in Table 6. Since faith in physicians is paramount
to effective coping in ICD patients, it is essential to build up a trustful
physician–patient relationship and to offer easy access to physician
support and advice in the case of problems and uncertainties
(Table 7). Merely listening to patient concerns may reduce their
worries and can by itself improve coping. Active problem-oriented
coping is often helpful for adapting to new challenges such as shocks
and can be supported by providing information about heart disease,
the ICD, and how the ICD works. Even a few minutes more can
make a difference, reduce patients’ uncertainties and their suffering.
Hence, when patients have received an ICD shock, sufficient time
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Table 5 Continuum of shocks, coping, and distress
Arrhythmia Coping Distress Feelings, thoughts, and behaviours
Continuum No arrhythmia Optimism Reassurance ICD as ‘guardian angel’
Active coping Successful adjustment ICD doesn’t bother me
ATP only Faith in doctors Realistic fear ICD may fail
Single shock Depressive coping Adjustment disorder Uncertain if ICD keeps me safe
Shock phobia Avoid activities that might trigger shocks
Multiple shocks Distraction/denial Moderate depression/agoraphobia Avoid any activities, withdraw
Electric storm Catastrophizing Dysthymia/generalized anxiety Lose interest/confidence in life, permanent worry
Resignation PTSD/personality change Permanent threat and arousal
Severe/recurrent depression Wanting to be dead
Modified from Sears and Conti.12
Figure 4 Supposed vicious circle of shocks and distress.










shouldbe spent withpatients toprovide relevant information, answer-
ing patients’ questions, and listening to worries and concerns.
During phases of acute distress, patients may be unable to
process information effectively, which may necessitate repeated
explanations. Patients should be asked what they have understood
and whether they still have concerns and unanswered questions.
Family support and support groups
Family support is critical for the ICD patient, both in terms of
instrumental and emotional support. However, families and in par-
ticular partners of ICD patients are faced with a number of
uncertainties and fears that may lead to even higher levels of dis-
tress than in patients. Advice how to cope with a partner’s ICD
and heart disease has been published elsewhere.105
One further option can be the referral to self-help groups, if
they are locally available, or implementation of a clinic-associated
support group for ICD patients. Patients with sufficient internet
experience can also be invited to join forums for ICD patients
on the internet.
Treatment and management of distress in
clinical practice
Data on the treatment of comorbid distress in ICD patients are
limited. Current reviews and treatment recommendations mainly
advocate the use of techniques for psychological crisis intervention,
cognitive behavioural therapy, relaxation, telephone counselling,
exercise, and SSRIs.94,106,107 It is important to keep in mind that
some psychotropic substances may exert a marked QT-prolonging
effect. There is no evidence to support differential assignment of
individual patients to specific treatments or combinations. Careful
individual assessment and counselling (see above) is therefore rec-
ommended for all ICD patients receiving shocks. Patients should
be encouraged to maintain or resume normal life as soon as possible
in order to prevent phobic avoidance behaviour.108 In the case of
persisting distress or psychopathology, a mental health expert
should be involved. In the absence of data comparing different
psychotherapeutic approaches, any treatment of individual psycho-
pathology by means of established psychotherapeutic techniques
can be recommended depending on local availability.
Psychotropic drug treatment should be prescribed by physicians
knowledgeable of the specific demands of psychopharmacotherapy
in cardiac patients. For theoretical reasons, antidepressants
without anticholinergic, or class I antiarrhythmic effects such as
SSRIs, appear preferable, although no specific evidence from con-
trolled trials in ICD patients exists.
Summary
The management of ICD patients after shock therapy varies,
depending on the number of shocks, their nature (appropriate
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Table 6 Recommended measures to identify high-risk patients post-shock
Risk factor Questionnaire Number of items Minutes for patients to complete Available in ≥3 languages
ICD concerns ICDCa 8 3–5 Yes
Anxiety FSASa 10 3–5 Yes
HADS-Ab 7 3 Yes
STAI (state only)b 20 3–6 Yes
Depression HADS-Db 7 3 Yes
PHQ-9b 9 3 Yes
Post-traumatic symptoms IES-Rb 22 10 Yes
Type D personality DS14b 14 5 Yes
DS14, Type D Scale; FSAS, Florida Shock Anxiety Scale; HADS, Hospital Anxiety and Depression Scale; ICDC, ICD Concerns Questionnaire; IES-R, Impact of Event Scale Revised;
PHQ-9, Patient Health Questionnaire; STAI, Spielberger’s State-Trait Anxiety Inventory.
aDisease-specific.
bGeneric.
Table 7 Ten practice tips for preventing and reducing
shock-induced distress
General measures
Establish trustful relationship with patients and partners
Establish trustful relationship with mental health expert inside or
outside the team
Listen to patients and leave room for questions and emotions
Preventive measures
Provide information (including patient brochures) and answer
patients’ questions about the ICD and related topics before and
after implantation. Explain that the ICD may save the patient’s life
but emphasize that it does not cure heart disease
Discuss participation in comprehensive rehabilitation and
encourage regular exercise adapted to individual preference and
physical capacity
Assessment and basic treatments
Regularly explore beliefs, health resources, and distress (both
pre-existing and newly developed) in person or via telephone calls
Offer quick help if shocks and/or distress occur
Ask for subjective effects of shock (e.g. sensory and emotional
perception, interpretation, behavioural consequences) and
encourage resumption of activities as soon as possible
Explore patient needs for more information and support
Provide reassurance and referral to a mental health expert,
structured psychosocial intervention, and/or support group as
appropriate










or inappropriate), and the patient’s clinical condition. The conti-
nuum of care ranges from single shocks without clinical instability
that permit assessment in due course performed either in-office or
remotely to repeated shocks with haemodynamic instability that
mandate emergency hospitalization. Implantable cardiac defibrilla-
tor interrogation establishes the diagnosis of supraventricular or
ventricular arrhythmias and recognizes device malfunction. Pro-
gramming the device algorithms that discriminate supraventricular
from ventricular arrhythmias reduce inappropriate shocks. Appro-
priate shocks can be reduced by reprogramming ATP parameters,
based on the response of stored VTs to ATP attempts and on the
haemodynamic tolerance of previous VT episodes. Clinical assess-
ment aims at the identification of triggering factors, such as myo-
cardial ischaemia, decompensated heart failure, and electrolyte
abnormalities. Antiarrhythmic agents can reduce episodes of
supraventricular and ventricular arrhythmias and may decrease
the VT rate, rendering rapid VTs amenable to successful ATP. If
antiarrhythmic regimens fail, substrate modification by catheter
ablation in an experienced centre decreases arrhythmic burden.
Patient management after ICD shocks needs to be re-evaluated
during frequent follow-up visits, and device reprogramming and/
or medical treatment adjustments are occasionally required.
Particular emphasis should be given to psychological distress,
commonly observed after ICD shocks. Reassurance often suffices,
but specialized assessment and counselling may be necessary in
selected patients.
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